Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

AutekBio to Build Largest Biologic CMO in Asia

publication date: Mar 9, 2010
 | 
author/source: Richard Daverman, PhD
AutekBio, Inc., with headquarters in the Bay Area of California but operations in China, will build Asia’s largest biologic CMO facility in southern Beijing. To construct the facility, AutekBio signed a deal securing $100 million in venture capital from private and government sources. Contributing to the capital raise were SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, Beijing’s Municipal Government’s venture capital group.

The new joint venture will build a world class R&D and manufacturing center in southern Beijing to service international biologic developments, with combined volumes of bioreactors up to 20,000 liters in multiple production lines (trains).

“I am extremely pleased with this joint investment. This will allow us to build one of the largest biologic CMOs in Asia,” said Julius Li, the CEO of AutekBio, Inc. “The newly established facility and company will provide, for the first time, manufacturing services in China fully conforming to the US FDA and EU EMEA cGMP standards, for global biopharmaceutical needs.”

According to Li, the facility will produce protein-based medicines that combine high quality with cost efficiency. The firm will benefit from financial, regulatory and other support from the Chinese government for the biotech industry, he said.

AutekBio was founded in 2006. One year after its beginning, the company singed a biologic CMO contract with Jiangsu Hengrui Pharmaceutical Corp. for a cancer MAb drug that was one of the largest CMO contracts in China’s pharmaceutical industry.

AutekBio offers proprietary, state-of-the-art technologies to the international bio-pharmaceutical market. Its wholly owned operation division in Beijing conducts both contract research and contract manufacturing business. AutekBio’s core technologies include engineering cell line development, process development and large-scale high yield biologic production using mammalian cell culture platforms.

Suma Ventures, a cross-border China/US venture capital firm, focuses on high-tech and the life science industry. With an entrepreneurial background, Suma often plays an active role in the founding and value creation of its portfolio companies, which include CROs, CMOs, antibody and small molecule anti-cancer drug development technology companies. The firm seeks to combine the best resources of Silicon Valley and China to build first-rank life science companies in China.

Disclosure: none.

 

Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China